Cannabis Pharmaceuticals: Company With Ties To Groundbreaking Medical Developments Pursues Cannabinoid-Based Medicines

Phytanix Bio, a preclinical stage pharmaceutical company, has released an updated investor deck. The presentation showcases a business strategy aimed at developing new cannabinoid-based pharmaceuticals. The company, which has ties to historical pharmaceutical developments in the cannabis industry, was recently acquired by Chain Bridge I.

The new company, named Phytanix Inc., hopes to take a piece of a global cannabis pharmaceuticals market, with its estimated total market value of $3.4 billion.

"We are excited to share our new investor deck, which provides a comprehensive overview of Phytanix Bio's vision and progress,” said Barrett Evans, CEO of Phytanix Bio. “Our team is dedicated to advancing our pipeline of cannabinoid-based medicines, and this presentation outlines our path forward and the significant opportunities ahead."

Business Model And Revenue Streams

According to the deck, Phytanix business model focuses on developing by clinically testing cannabinoid-based therapeutics. The company's strategy includes obtaining regulatory approvals, and establishing intellectual property rights. Also forming strategic partnerships for clinical trials and manufacturing to get exclusivity on pharmaceuticals.

Phytanix primary revenue streams are expected from developments, including:

• Bladder Pain Syndrome (BPS): Developing a simplified cannabis extract for treating bladder pain syndrome. The projected launch value is $4.123 billion.
• Treatment-Resistant Focal Seizures in Adults (TRFSA): Developing a chemically synthesized stilbenoid for treatment-resistant focal seizures. The projected launch value is $2.506 billion.

Read Also: $58M Merger: Chain Bridge I Acquires Cannabinoid Medicines Innovator, Eyes Nasdaq Listing

Intellectual Property And Data Exclusivity

Phytanix management has a more than relevant background developing cannabinoids-based pharmaceuticals: CEO Colin Stott was R&D operations director at GW Pharmaceutical, the company that developed Epidiolex and Sativex. Epidiolex was approved in 2018 by FDA as the first cannabinoids based pharmaceutical medicine of the modern era, while Sativex was approved in the UK in 2010.

Phytanix intellectual property portfolio includes patents and proprietary technologies. At a minimum, a new extract-based medicine would be entitled to regulatory data exclusivity for five years in the U.S. and ten years in Europe. Data exclusivity prevents other applicants from using the data in support of another marketing authorization. This would protect Phytanix innovations from generic competition.

• Read Next: Biden’s Greenlight: What To Know About Fed-Regulated Marijuana, Markets, Legal Circuits And Compliance